Amendments to the Specification:

Please replace the paragraph **[0049]** with the following rewritten paragraph:

[0049] More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, ~~pBluescript~~ pBLUESCRIPT SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmids or vectors may be used as long as they are replicable in the host.

Please replace the paragraph **[0098]** with the following rewritten paragraph:

[0098] Therefore, the core 1 ß3-galactosyl transferase enzymes coexpressed with Cosmc-1 of the present invention can be used for *in vitro*

synthesis of glycosulfopeptides to block selectin:ligand interactions. Other potential uses for the core 1 ß3-galactosyl transferase enzymes coexpressed with Cosmc-1 of the present invention which can be envisioned include diagnostic tests for the rare Tn-syndrome or IgA ~~nepropathy~~,nephropathy as well as for therapy of these disorders.